Ionis Pharmaceuticals Inc (IONS)
33.98
+0.04
(+0.12%)
USD |
NASDAQ |
Nov 22, 16:00
33.98
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Research and Development Expense (Quarterly): 219.76M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 219.76M |
| June 30, 2024 | 222.06M |
| March 31, 2024 | 214.22M |
| December 31, 2023 | 256.56M |
| September 30, 2023 | 215.33M |
| June 30, 2023 | 229.93M |
| March 31, 2023 | 197.81M |
| December 31, 2022 | 308.27M |
| September 30, 2022 | 182.99M |
| June 30, 2022 | 180.76M |
| March 31, 2022 | 161.13M |
| December 31, 2021 | 179.58M |
| September 30, 2021 | 184.77M |
| June 30, 2021 | 139.31M |
| March 31, 2021 | 139.80M |
| December 31, 2020 | 170.78M |
| September 30, 2020 | 125.08M |
| June 30, 2020 | 122.26M |
| March 31, 2020 | 116.95M |
| December 31, 2019 | 148.74M |
| September 30, 2019 | 104.37M |
| June 30, 2019 | 106.16M |
| March 31, 2019 | 106.42M |
| December 31, 2018 | 113.45M |
| September 30, 2018 | 95.26M |
| Date | Value |
|---|---|
| June 30, 2018 | 101.83M |
| March 31, 2018 | 104.07M |
| December 31, 2017 | 128.29M |
| September 30, 2017 | 80.21M |
| June 30, 2017 | 83.51M |
| March 31, 2017 | 82.64M |
| December 31, 2016 | 101.15M |
| September 30, 2016 | 84.63M |
| June 30, 2016 | 77.57M |
| March 31, 2016 | 80.96M |
| December 31, 2015 | 101.33M |
| September 30, 2015 | 88.51M |
| June 30, 2015 | 68.01M |
| March 31, 2015 | 64.45M |
| December 31, 2014 | 67.95M |
| September 30, 2014 | 61.09M |
| June 30, 2014 | 59.26M |
| March 31, 2014 | 53.45M |
| December 31, 2013 | 57.43M |
| September 30, 2013 | 45.66M |
| June 30, 2013 | 42.63M |
| March 31, 2013 | 38.31M |
| December 31, 2012 | 42.76M |
| September 30, 2012 | 36.55M |
| June 30, 2012 | 40.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
116.95M
Minimum
Mar 2020
308.27M
Maximum
Dec 2022
185.80M
Average
181.87M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen Inc | 542.70M |
| Alnylam Pharmaceuticals Inc | 270.93M |
| Biomarin Pharmaceutical Inc | 184.90M |
| Amicus Therapeutics Inc | 26.16M |
| Arbutus Biopharma Corp | 14.27M |